---
schema_version: "secwatch.filing_event.v1"
accession: "0001552000-22-000011"
form_type: "8-K"
ticker: "MPLX"
cik: "0001552000"
company_name: "MPLX LP"
filed_at: "2022-04-21T23:59:59+00:00"
generated_at: "2026-06-26T05:42:38.419251+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MPLX CEO Michael Hennigan discloses throat cancer diagnosis; says prognosis is curable

## Summary
- CEO diagnosed with throat cancer, caught early and considered curable per leading medical institutions.
- Will undergo seven-week radiation and chemotherapy treatment while continuing as CEO with limited travel.
- Board fully apprised and supportive; no leadership change announced.

## SEC filing metadata
- accession: 0001552000-22-000011
- form_type: 8-K
- ticker: MPLX
- cik: 0001552000
- company_name: MPLX LP
- filed_at: 2022-04-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1552000/000155200022000011/0001552000-22-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1552000/000155200022000011/mplx-20220421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001552000-22-000011
- JSON: https://secwatch.observer/filing/0001552000-22-000011.json
- Plain text: https://secwatch.observer/filing/0001552000-22-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.